# A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors

> **NCT05892653** · PHASE1 · TERMINATED · sponsor: **ABM Therapeutics Shanghai Company Limited** · enrollment: 15 (actual)

## Conditions studied

- Primary Malignant Brain Tumor

## Interventions

- **DRUG:** ABM-1310

## Key facts

- **NCT ID:** NCT05892653
- **Lead sponsor:** ABM Therapeutics Shanghai Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-30
- **Primary completion:** 2024-08-27
- **Final completion:** 2024-08-27
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Adjustment of the applicant's research and development strategy
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05892653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05892653, "A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05892653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*